Beyondspring (BYSI) AI Stock Analysis

• Market Cap: $63.74M
• Dividend Yield: N/A
• Average Volume (3M): 478.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 41,122,320
• 10 Day Avg. Volume: 1,393,566
• 30 Day Avg. Volume: 478,066
• PEG Ratio: 0.12
• Price to Book (P/B): -1.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.89
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.48K
• Enterprise Value/Ebitda: -6.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $2.00 ▲(20.48% Upside)

The score is driven primarily by very weak financial performance (no meaningful revenue, persistent losses, negative equity, and ongoing cash burn requiring external funding). Technicals are also soft with the stock trading below major moving averages and negative MACD. Valuation is constrained by negative earnings and no dividend support.

Positive Factors

Innovative Product Pipeline

The development of Plinabulin as a novel cancer therapy positions BeyondSpring for potential breakthroughs in oncology, offering long-term growth opportunities if successful in clinical trials and commercialization.

Strategic Partnerships

By leveraging partnerships and licensing agreements, BeyondSpring can enhance its market reach and financial stability, potentially securing funding and expertise to advance its drug candidates.

Focus on High Unmet Needs

Targeting high unmet medical needs in cancer treatment can lead to significant market demand and competitive advantage, driving long-term growth if therapies prove effective.

Negative Factors

Zero Revenue

The absence of revenue in 2024 indicates severe financial challenges, limiting the company's ability to invest in R&D and sustain operations without external funding.

Negative Equity

Negative equity suggests liabilities exceed assets, posing significant financial risk and limiting the company's ability to secure additional financing on favorable terms.

Reliance on External Funding

Dependence on external funding to sustain operations highlights financial instability and raises concerns about long-term viability without a clear path to profitability.

Beyondspring Business Overview & Revenue Model

Company Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

How the Company Makes Money

BeyondSpring generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to bring its products to market through a combination of direct commercialization, partnerships, and licensing agreements with other pharmaceutical companies. Revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from its lead product, Plinabulin, once it receives regulatory approval and is commercialized. BeyondSpring may also receive funding through research grants and collaborations with academic and research institutions.

Beyondspring Financial Statement Overview

Summary

Financials are very weak with effectively no revenue, ongoing net losses, and consistently negative operating and free cash flow. While losses and cash burn have improved versus prior years, negative stockholders’ equity and continued funding needs create elevated financing/dilution risk.

Income Statement

The income statement remains very weak: revenue is effectively nonexistent in recent years (2023–2024 annual reports show $0 revenue), with a sharp revenue drop in 2024 versus 2022 levels. Losses are persistent, though the loss profile has improved meaningfully from 2020–2022 to 2023–2024 (net loss narrowed from roughly -$33M in 2022 to about -$21M in 2023 and -$11M in 2024). Despite improving expense control, the company is still far from profitability and has limited evidence of a sustainable commercial revenue base.

Balance Sheet

Leverage is low in absolute dollars (total debt under ~$1M in 2024), which is a positive. However, the balance sheet shows a major weakness: stockholders’ equity is negative in 2022–2024 (about -$33M in 2024), indicating accumulated losses have overwhelmed the equity base and increasing financial fragility. Total assets have also declined materially from 2020 levels, suggesting cash burn has reduced the asset base over time.

Cash Flow

Cash flow quality is pressured by ongoing cash burn: operating cash flow and free cash flow are consistently negative each year. There is improvement in cash usage versus prior years (operating cash flow improved from roughly -$47M in 2021 to about -$16M in 2023–2024), but the business still requires external funding to sustain operations. Free cash flow generally tracks net losses closely, indicating limited non-cash cushioning and continued reliance on cash outflows to run the business.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	1.35M	1.35M	180.00K
Gross Profit	-21.00K	0.00	-302.00K	1.35M	1.35M	180.00K
EBITDA	-7.77M	-8.47M	-13.62M	-34.96M	-64.49M	-63.66M
Net Income	-598.00K	-11.12M	-21.03M	-33.28M	-64.18M	-60.97M
Balance Sheet
Total Assets	29.48M	34.31M	24.81M	46.22M	81.65M	117.04M
Cash, Cash Equivalents and Short-Term Investments	12.62M	2.92M	15.34M	37.27M	72.37M	109.54M
Total Debt	406.00K	589.00K	847.00K	4.96M	3.58M	4.31M
Total Liabilities	49.29M	48.60M	48.27M	49.23M	60.73M	25.22M
Stockholders Equity	-31.77M	-32.90M	-26.80M	-5.98M	26.68M	88.34M
Cash Flow
Free Cash Flow	-14.67M	-16.67M	-16.57M	-28.18M	-50.09M	-43.80M
Operating Cash Flow	-14.62M	-16.44M	-16.47M	-28.15M	-47.24M	-43.74M
Investing Cash Flow	18.77M	-12.01M	-100.00K	18.25M	-20.41M	-52.00K
Financing Cash Flow	279.48K	26.79M	4.00K	3.43M	1.00K	117.83M

Beyondspring Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.82, and below the 200-day MA of 1.91, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 40.53 is Neutral, neither overbought nor oversold. The STOCH value of 26.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BYSI.

Beyondspring Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XFOR	52 Neutral	$316.52M	-0.37	-156.87%	―	2925.73%	-294.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRLD	47 Neutral	$111.53M	-1.18	-103.99%	―	250.00%	15.15%
GANX	46 Neutral	$75.39M	-3.00	-261.72%	―	―	42.29%
ABVC	44 Neutral	$49.31M	-9.32	-40.32%	―	56.52%	75.22%
BYSI	43 Neutral	$63.74M	―	―	―	―	―
PSTV	40 Underperform	$42.63M	―	―	―	-8.16%	22.44%

Beyondspring Corporate Events

Beyondspring Delays Second Closings of Share Sale

BeyondSpring Inc. announced that it entered into a Preferred Share Purchase Agreement on January 24, 2025, with Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED, and Mapfil Investment Limited to sell a total of 8,333,637 Series A-1 Preferred Shares of SEED Therapeutics Inc. for approximately $35.4 million. The Second Closings of these transactions, initially expected by December 15, 2025, are now anticipated to be completed in the first half of 2026, though the exact timing remains uncertain.

BeyondSpring Completes $2 Million Securities Agreement

BeyondSpring Inc. announced that on November 21, 2025, it completed a Securities Purchase Agreement with Ray Beauty Group Limited, resulting in the issuance and sale of 800,000 shares at $2.50 per share, raising $2 million in gross proceeds. The agreement includes a 60-day lock-up period for the investor, restricting the sale or derivative transactions of the shares without the company’s consent, potentially impacting BeyondSpring’s market positioning and investor relations.